The Qiming US Healthcare Fund led a $10 million Series A funding of Platelet BioGenesis, a Boston startup developing a process to make platelets from stem cells. Platelets, which have a useful shelf life of just two days, are sourced from human donors in a 90-minute procedure. Platelet BioGenesis’ technology would guarantee a consistent supply. In January, Qiming, a China-based venture capital investor, announced plans for the $125 million US Fund to support innovative US biopharmas whose products would address needs in China.
Source: ChinaBio Today
